AIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AIM ImmunoTech Inc is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak technical indicators, poor financial performance, and no strong positive catalysts to support a bullish outlook. Additionally, there are no proprietary trading signals to suggest a short-term opportunity.
The technical indicators are bearish. The MACD is negative and expanding downward, RSI is at 21.011 indicating oversold conditions but not a clear buy signal, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.806, with resistance levels significantly higher, suggesting limited upward momentum in the short term.
The company has launched a rights offering to raise $12 million to support late-stage pancreatic cancer treatment, which could potentially fund future growth if the treatment proves successful.
The rights offering may dilute existing shareholder value. Additionally, the company's financial performance has significantly deteriorated, with declining revenue (-25.71% YoY), widening net losses (-11.24% YoY), and a sharp drop in EPS (-75.51% YoY). Gross margin is also deeply negative (-161.54%).
In Q3 2025, AIM ImmunoTech reported a significant decline in revenue, net income, EPS, and gross margin. These metrics indicate poor financial health and lack of profitability, making the stock unattractive for long-term investment.
No analyst rating or price target changes available for AIM ImmunoTech.
